State-of-the-art DNA sequencing tools
MSI-high tumors are a particular type of tumors, characterized by DNA errors (mutations) that are most often found in colorectal or endometrial cancer patients. Colorectal cancer patients with an MSI-high status show a better prognosis and require different therapies, therefore accurate testing is necessary. The group of Diether Lambrechts (VIB-KU Leuven) identified 7 novel biomarkers to test colorectal cancer samples on their MSI-status.
The set of MSI biomarkers identified by Diether Lambrechts’ lab was exclusively licensed to Biocartis from VIB in 2013. This marked the start of a collaborative MSI research program, with the aim to support the development of a fully automated MSI test on Biocartis’ IdyllaTM platform.
Biocartis launched its innovative and fully automated Idylla™ MSI Assay in the summer of 2018. This test includes the 7 MSI biomarkers identified and provides fast and accurate information on a patient’s MSI status directly from a single sample of formalin fixed, paraffin embedded (FFPE) colorectal cancer tumor tissue.